TCGA-AN-A0FF-01A-11R-A034-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 6
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.560
- ESTROGEN_RESPONSE_EARLY+0.390
- ESTROGEN_RESPONSE_LATE+0.290
- INTERFERON_GAMMA_RESPONSE+0.290
- COMPLEMENT+0.200
- PEROXISOME+0.190
- MITOTIC_SPINDLE+0.180
- DNA_REPAIR+0.170
- PI3K_AKT_MTOR_SIGNALING+0.170
- G2M_CHECKPOINT+0.160
Top 10 suppressed
- MYC_TARGETS_V1-0.330
- MYC_TARGETS_V2-0.290
- HYPOXIA-0.270
- PANCREAS_BETA_CELLS-0.250
- NOTCH_SIGNALING-0.240
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.190
- SPERMATOGENESIS-0.180
- MTORC1_SIGNALING-0.140
- UNFOLDED_PROTEIN_RESPONSE-0.130
- APICAL_JUNCTION-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A2-A0YC-01A-11R-A109-07 | — | B | 0.676 |
| 2 | TCGA-E9-A1R4-01A-21R-A14D-07 | — | C | 0.624 |
| 3 | TCGA-EW-A1P5-01A-11R-A144-07 | — | B | 0.607 |
| 4 | TCGA-EW-A1J5-01A-11R-A13Q-07 | — | B | 0.583 |
| 5 | SRR35579846 | — | D | 0.580 |
| 6 | TCGA-AR-A24R-01A-11R-A169-07 | — | B | 0.571 |
| 7 | TCGA-E9-A22H-01A-11R-A157-07 | — | B | 0.561 |
| 8 | TCGA-S3-A6ZF-01A-32R-A32P-07 | — | B | 0.558 |
| 9 | 06ef2350-1dd1-46e9-a1ac-8fc731a6abc7 | — | — | 0.556 |
| 10 | SRR6013559 | — | cohortMD2 | 0.551 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.560 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.390 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.290 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.290 | Idelalisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.160 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.140 | Inavolisib | — uncovered |
| COAGULATION | 0.130 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.120 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.070 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.070 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.070 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.060 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |